Eptifibatide in percutaneous coronary intervention. A review.
Percutaneous coronary angioplasty and stenting is widely used for the treatment of patients with coronary artery disease. Glycoprotein (GP) IIb-IIIa inhibitors represent a new class of drugs with proven efficacy in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). One of these, eptifibatide (Integrilin feminine, COR), is a small molecule inhibitor of glycoprotein IIb-IIIa receptors which has been studied extensively in patients undergoing PCI. In both IMPACT II and ESPRIT trials, patients treated with eptifibatide experienced a reduction in the rate of ischemic complications compared to those treated with placebo. These landmark studies, which are the focus of this review, emphasize the importance of considering the use of GP IIb-IIIa inhibitors in all patients undergoing PCI.
Duke Scholars
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Stents
- Risk Assessment
- Randomized Controlled Trials as Topic
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Placebos
- Peptides
- Multicenter Studies as Topic
- Middle Aged
- Humans
Citation
Published In
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Stents
- Risk Assessment
- Randomized Controlled Trials as Topic
- Platelet Glycoprotein GPIIb-IIIa Complex
- Platelet Aggregation Inhibitors
- Placebos
- Peptides
- Multicenter Studies as Topic
- Middle Aged
- Humans